학술논문
Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis
Document Type
Article
Author
Source
In ESMO Open December 2023 8(6)
Subject
Language
ISSN
2059-7029